4.5 Article

Optimal and ethical designs for hypothesis testing in multi-arm exponential trials

Journal

STATISTICS IN MEDICINE
Volume 40, Issue 11, Pages 2578-2603

Publisher

WILEY
DOI: 10.1002/sim.8919

Keywords

multiple treatments; response adaptive randomization; survival trials; unequal allocations

Funding

  1. PhD Program GlaxoSmithKline Biologicals SA

Ask authors/readers for more resources

The study proposes a constrained optimization approach for addressing unequal allocation demands in multi-arm clinical trials, which enhances test power while adhering to ethical constraints. This method shows excellent performance in both uncensored and censored scenarios, making it particularly useful for clinical trial designs in oncology and infectious disease research, where ethical considerations are crucial.
Multi-arm clinical trials are complex experiments which involve several objectives. The demand for unequal allocations in a multi-treatment context is growing and adaptive designs are being increasingly used in several areas of medical research. For uncensored and censored exponential responses, we propose a constrained optimization approach in order to derive the design maximizing the power of the multivariate test of homogeneity, under a suitable ethical constraint. In the absence of censoring, we obtain a very simple closed-form solution that dominates the balanced design in terms of power and ethics. Our suggestion can also accommodate delayed responses and staggered entries, and can be implemented via response adaptive rules. While other targets proposed in the literature could present an unethical behavior, the suggested optimal allocation is frequently unbalanced by assigning more patients to the best treatment, both in the absence and presence of censoring. We evaluate the operating characteristics of our proposal theoretically and by simulations, also redesigning a real lung cancer trial, showing that the constrained optimal target guarantees very good performances in terms of ethical demands, power and estimation precision. Therefore, it is a valid and useful tool in designing clinical trials, especially oncological trials and clinical experiments for grave and novel infectious diseases, where the ethical concern is of primary importance.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available